Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in...
18 KB (1,555 words) - 14:12, 10 August 2024
developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations". Debiopharm. 23 June 2009...
14 KB (981 words) - 11:38, 23 March 2024
Retrieved 7 October 2020. "Debiopharm Group™ presents the 'Debiopharm Group Life Sciences Award 2013' and two 'Junior Debiopharm Group Life Sciences Awards...
15 KB (1,199 words) - 14:11, 26 June 2024
Daiichi Sankyo (2005– ) Danco (2000– ) Darou Pakhsh (1956– ) Dawa (1994– ) Debiopharm (1979– ) Dechra (1997- ) Delix (2019– ) Dentsply Sirona (1899– ) Dermapharm...
34 KB (2,168 words) - 15:30, 26 August 2024
Balderton Capital and $2.7 million invested by the private equity arm of Debiopharm Group. Chief executive Stelio Tzonis said that use of the funding will...
4 KB (356 words) - 11:19, 23 April 2022
headquarters Cochlear Limited Basel Basel-Stadt European headquarters Debiopharm Lausanne Vaud Global headquarters Edwards Lifesciences Nyon Vaud European...
13 KB (690 words) - 03:24, 15 July 2024
2024. Debiopharm Group Press Release (November 2010) "Abionic wins the 'Prix Debiopharm Valais pour les Sciences de la Vie", www.debiopharm.com "Abionic...
14 KB (1,246 words) - 22:58, 5 August 2024
spin-off to date to emerge from PSI. In 2017, the Lausanne-based company Debiopharm licensed the active substance 177Lu-PSIG-2, which was developed at the...
48 KB (5,849 words) - 08:26, 5 July 2024
Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.[citation...
7 KB (570 words) - 16:49, 4 February 2024
Retrieved 30 June 2022. "Start". Lu.se. Retrieved 30 June 2022. "Debiopharm". Debiopharm.com. Retrieved 30 June 2022. [2] [dead link] "ALTA". Altaweb.eu...
7 KB (536 words) - 00:58, 8 July 2023